• Revenue and other income up 77% to $7.28m
• Loss after tax up 5% to $22.38m
• Positive clinical data reported for key trials

Immutep Limited has reported its half-year financial results for the period ended 31 December 2024. Revenue and other income increased 77% to $7.28m, while loss after tax was up 5% to $22.38m. The increase in loss was mainly due to higher R&D and IP expenses, partially offset by increased interest income, grant income, and lower corporate expenses. The company continued to make progress on its key clinical trials, including the Phase III TACTI-004 trial in first-line non-small cell lung cancer, the Phase IIb TACTI-003 trial in first-line head and neck squamous cell carcinoma, and the Phase II AIPAC-003 trial in metastatic breast cancer. Positive data was reported from the TACTI-003 and EFTISARC-NEO trials, showing promising efficacy and safety. Immutep also advanced its Phase I IMP761 trial for autoimmune diseases and continued enrollment in the INSIGHT-003 and INSIGHT-005 trials. Overall, the company remains focused on advancing its lead product candidate eftilagimod alpha and other pipeline assets through clinical development towards potential regulatory approvals.